DeFloria LLC, a collaboration between Charlottes Web Holdings Inc (OTCQX:CWBHF) and AJNA BioSciences PBC, has launched the Phase 1 clinical trial of AJA001, a full-spectrum hemp botanical drug.
The trial, which marks the first human testing of this innovative substance, began with dosing its first cohort in September and aims to evaluate its safety, tolerability and pharmacokinetic properties.
Details Of The AJA001 Clinical Trial
AJA001, derived from one of Charlotte’s Web’s patented hemp cultivars is expected to enroll approximately 64 participants in Brisbane, Australia. The study will explore both single ascending doses and a seven-day multiple ascending dose phase.
Expert Insights
“Our phase 1 entrance marks a critical milestone in AJA001’s ...